Physician profile
John H Howard
NPI 1952515736
$19,800.03
in general payments reported to CMS, 2019-2025
47 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $17.25 · 2021: $51.17 · 2022: $420 · 2023: $18K · 2024: $664 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,859 · Consulting Fee: $8,540 · Food and Beverage: $1,756 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,858.52 |
| Consulting Fee | $8,540.00 |
| Food and Beverage | $1,755.93 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17,518.33 | 2022-2025 | Keytruda, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $328.54 | 2019-2025 | Libtayo |
| Eisai INC. | $226.24 | 2022-2025 | |
| Janssen Biotech, INC. | $164.69 | 2023-2025 | Erleada, Balversa, Darzalex |
| Incyte Corporation | $135.57 | 2020-2025 | Monjuvi, Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $108.88 | 2022 | |
| Abbvie INC. | $83.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $82.24 | 2022-2025 | Imfinzi, Calquence |
| Taiho Oncology, INC. | $71.61 | 2023-2024 | |
| Histosonics, INC. | $71.45 | 2025 | |
| Genentech USA, INC. | $71.36 | 2024-2025 | Tecentriq, Polivy, Phesgo |
| Tempus Ai, INC | $63.44 | 2024 | |
| Stemline Therapeutics INC. | $59.45 | 2023-2024 | Orserdu |
| Novartis Pharmaceuticals Corporation | $57.44 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $48.22 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.